PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17532004-8 2007 Rosiglitazone, a Peroxisome proliferator activated receptor gamma (PPARgamma) activator, substantially elevated expression of adiponectin in cultured cardiomyocytes and its secretion into cultured media. Rosiglitazone 0-13 adiponectin, C1Q and collagen domain containing Rattus norvegicus 126-137 18199331-13 2008 Rosiglitazone 10 mg/kg/day or pioglitazone 30 mg/kg/day increased the expression of PPAR-gamma and adiponectin in adipose tissue, confirming that they were activating PPAR-gamma in inflammatory conditions, although an increase in fat mass percentage was observed for the most anti-arthritic dose. Rosiglitazone 0-13 adiponectin, C1Q and collagen domain containing Rattus norvegicus 99-110 18070756-9 2007 ROSI administration also decreased circulating insulin, leptin, and triglycerides and increased circulating adiponectin levels; however, these effects were reversed on stopping treatment. Rosiglitazone 0-4 adiponectin, C1Q and collagen domain containing Rattus norvegicus 108-119 19531641-3 2009 Here we demonstrated an increased level of adiponectin mRNA and protein expression as well as protein secretion in response to rosiglitazone treatment in L6 muscle cells. Rosiglitazone 127-140 adiponectin, C1Q and collagen domain containing Rattus norvegicus 43-54 19531641-7 2009 Induction of obesity and insulin resistance in rats by feeding a high-fat high-sucrose diet also led to decreased muscle HMW adiponectin content that could be corrected by rosiglitazone treatment. Rosiglitazone 172-185 adiponectin, C1Q and collagen domain containing Rattus norvegicus 125-136 19531641-9 2009 We also demonstrate that skeletal muscle adiponectin production is altered in animal models of obesity and diabetes and that these changes can be corrected by rosiglitazone. Rosiglitazone 159-172 adiponectin, C1Q and collagen domain containing Rattus norvegicus 41-52 17261469-8 2007 In addition, rosiglitazone increased plasma levels of adiponectin fourfold from 4.3 +/- 0.1 to 18.4 +/- 0.6 mug/mL (P < .05). Rosiglitazone 13-26 adiponectin, C1Q and collagen domain containing Rattus norvegicus 54-65 17261469-10 2007 CONCLUSIONS: This study shows for the first time that in an animal model of MS, the insulin sensitizer, rosiglitazone, improves the metabolic profile and increases plasma levels of adiponectin and its gene expression. Rosiglitazone 104-117 adiponectin, C1Q and collagen domain containing Rattus norvegicus 181-192 17261469-11 2007 It is possible therefore that rosiglitazone exerts its beneficial effects by increasing the levels of adiponectin. Rosiglitazone 30-43 adiponectin, C1Q and collagen domain containing Rattus norvegicus 102-113 15734724-9 2005 In contrast, in RSG-treated ZDF rats, plasma adiponectin levels were nearly 4-fold higher than in lean control rats, primarily as a result of a large increase in the amount of low-molecular weight forms of adiponectin in circulation. Rosiglitazone 16-19 adiponectin, C1Q and collagen domain containing Rattus norvegicus 45-56 17130509-6 2006 Three-week treatment of SHRs with rosiglitazone and/or enalapril significantly reduced blood pressure, insulin resistance, fasting insulin, and ET-1 levels and increased adiponectin levels to values comparable with those observed in vehicle-treated WKY controls. Rosiglitazone 34-47 adiponectin, C1Q and collagen domain containing Rattus norvegicus 170-181 16157299-6 2005 Rosiglitazone significantly increased serum adiponectin concentration from 20 to 40 weeks of age (P<0.05), whereas fenofibrate reduced TNF-alpha concentration. Rosiglitazone 0-13 adiponectin, C1Q and collagen domain containing Rattus norvegicus 44-55 16157299-7 2005 The expression of visfatin and adiponectin mRNA in visceral fat deposits was elevated by rosiglitazone or fenofibrate treatments when compared to untreated OLETF rats (P<0.05), whereas, TNF-alpha mRNA was down-regulated by these drugs (P<0.05). Rosiglitazone 89-102 adiponectin, C1Q and collagen domain containing Rattus norvegicus 31-42 16157299-8 2005 These results suggest that rosiglitazone and fenofibrate may prevent type 2 diabetes by regulating adipocytokines including visfatin, adiponectin, and TNF-alpha. Rosiglitazone 27-40 adiponectin, C1Q and collagen domain containing Rattus norvegicus 134-145 16201273-11 2005 The decreased serum adiponectin was caused by the decreased expression of adiponectin mRNA in adipose tissue rather than the adiponectin receptors in the skeletal muscle, which could be improved by rosiglitazone. Rosiglitazone 198-211 adiponectin, C1Q and collagen domain containing Rattus norvegicus 20-31 16201273-11 2005 The decreased serum adiponectin was caused by the decreased expression of adiponectin mRNA in adipose tissue rather than the adiponectin receptors in the skeletal muscle, which could be improved by rosiglitazone. Rosiglitazone 198-211 adiponectin, C1Q and collagen domain containing Rattus norvegicus 74-85 16201273-11 2005 The decreased serum adiponectin was caused by the decreased expression of adiponectin mRNA in adipose tissue rather than the adiponectin receptors in the skeletal muscle, which could be improved by rosiglitazone. Rosiglitazone 198-211 adiponectin, C1Q and collagen domain containing Rattus norvegicus 74-85 15734724-9 2005 In contrast, in RSG-treated ZDF rats, plasma adiponectin levels were nearly 4-fold higher than in lean control rats, primarily as a result of a large increase in the amount of low-molecular weight forms of adiponectin in circulation. Rosiglitazone 16-19 adiponectin, C1Q and collagen domain containing Rattus norvegicus 206-217 20965162-0 2011 The ameliorating effect of rosiglitazone on experimental nonalcoholic steatohepatitis is associated with regulating adiponectin receptor expression in rats. Rosiglitazone 27-40 adiponectin, C1Q and collagen domain containing Rattus norvegicus 116-127 15130413-12 2004 At the same time, rosiglitazone increased adiponectin by 60% (P < 0.01), and improved insulin sensitivity by 149.6% (P < 0.01) as compared with the HF group. Rosiglitazone 18-31 adiponectin, C1Q and collagen domain containing Rattus norvegicus 42-53 12556350-6 2003 Whereas all three PPAR agonists lowered plasma triglyceride levels and lessened muscle long-chain acyl-CoAs, ragaglitazar and rosiglitazone had greater insulin-sensitizing action in muscle than Wy-14643, associated with a threefold increase in plasma adiponectin levels. Rosiglitazone 126-139 adiponectin, C1Q and collagen domain containing Rattus norvegicus 251-262 27508153-6 2016 Exercise training and rosiglitazone treatment respectively increased the expression of PPAR(peroxisome proliferators-activated receptor)-alpha, -beta/delta, -gamma, PGC-1alpha(PPAR-gamma coactivator-1alpha), adiponectin, GLUT-4(glucose transportor-4) and p-AMPK-alpha2(phospho-AMP activated protein kinase-alpha2) in EDL and SOL of diabetic, as compared to normal animals. Rosiglitazone 22-35 adiponectin, C1Q and collagen domain containing Rattus norvegicus 208-219 23918561-7 2013 Rimonabant, pair-fed control, and rosiglitazone groups showed decreased insulin resistance and increased adiponectin, with no differences between the rimonabant and pair-fed control groups. Rosiglitazone 34-47 adiponectin, C1Q and collagen domain containing Rattus norvegicus 105-116 22542658-0 2012 Effect of rosiglitazone on the expression of cardiac adiponectin receptors and NADPH oxidase in type 2 diabetic rats. Rosiglitazone 10-23 adiponectin, C1Q and collagen domain containing Rattus norvegicus 53-64 22542658-1 2012 This study investigated the effect of rosiglitazone on the expression of cardiac adiponectin receptors and NADPH oxidase in type 2 diabetic rats. Rosiglitazone 38-51 adiponectin, C1Q and collagen domain containing Rattus norvegicus 81-92 22120832-8 2012 On the other hand, both glitazones changed the distribution of adiponectin isoforms in plasma, leading to an increase in the S(A) of 21% by pioglitazone and 31% by rosiglitazone. Rosiglitazone 164-177 adiponectin, C1Q and collagen domain containing Rattus norvegicus 63-74 21423295-1 2011 The objective of this study was to investigate the modulation of metabolic dysfunctions, adiponectin levels, and cardiac dysfunctions of type 2 diabetes mellitus (T2DM) by a combination of the insulin sensitizer rosiglitazone and angiotensin receptor blocker telmisartan in an experimental rat model. Rosiglitazone 212-225 adiponectin, C1Q and collagen domain containing Rattus norvegicus 89-100 21423295-13 2011 Moreover, a combination of rosiglitazone and telmisartan offered more improvement in serum TGs and adiponectin, and restored the atrial inotropic response to adenosine. Rosiglitazone 27-40 adiponectin, C1Q and collagen domain containing Rattus norvegicus 99-110 30225267-0 2018 Rosiglitazone Elicits an Adiponectin-Mediated Insulin-Sensitizing Action at the Adipose Tissue-Liver Axis in Otsuka Long-Evans Tokushima Fatty Rats. Rosiglitazone 0-13 adiponectin, C1Q and collagen domain containing Rattus norvegicus 25-36 30225267-10 2018 More importantly, rosiglitazone attenuated the decreases in adipose adiponectin mRNA level, plasma adiponectin concentrations, and hepatic protein expression of adiponectin receptor-1 and receptor-2. Rosiglitazone 18-31 adiponectin, C1Q and collagen domain containing Rattus norvegicus 68-79 30225267-10 2018 More importantly, rosiglitazone attenuated the decreases in adipose adiponectin mRNA level, plasma adiponectin concentrations, and hepatic protein expression of adiponectin receptor-1 and receptor-2. Rosiglitazone 18-31 adiponectin, C1Q and collagen domain containing Rattus norvegicus 99-110 30225267-11 2018 Thus, we can draw the conclusion that rosiglitazone elicits an adiponectin-mediated insulin-sensitizing action at the adipose tissue-liver axis in obese rats. Rosiglitazone 38-51 adiponectin, C1Q and collagen domain containing Rattus norvegicus 63-74 24412557-9 2014 GW9662 also decreased the adiponectin levels; Both ethanol and GW9662 weakened the rosiglitazone-induced elevation of adiponectin levels in cultured VAT. Rosiglitazone 83-96 adiponectin, C1Q and collagen domain containing Rattus norvegicus 118-129 20965162-5 2011 Additionally, rosiglitazone increased circulating adiponectin, which was negatively correlated with serum TNF-alpha. Rosiglitazone 14-27 adiponectin, C1Q and collagen domain containing Rattus norvegicus 50-61 20094971-8 2010 Additionally, rosiglitazone exhibited an inhibitory effect on adiponectin release by both WAT explants, even though adiponectin mRNA was importantly upregulated only in inguinal explants. Rosiglitazone 14-27 adiponectin, C1Q and collagen domain containing Rattus norvegicus 62-73